An interventional study of ARC-IM Therapy in Spinal Cord Injury, SCI and SCI - Spinal Cord Injury, sponsored by Ecole Polytechnique Fédérale de Lausanne. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Ecole Polytechnique Fédérale de Lausanne · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Spinal Cord Injuries with a site in Switzerland — 25 open to participants now, 31 under way, none of them phase 3. Spinal Cord Injuries · Switzerland.
Among the 111 studies in Spinal Cord Injuries with a site in Switzerland, this one is the 52nd largest by planned enrollment of the 72 interventional ones that give a count, is one of 8 that started in 2026, is one of 59 with no phase, reaches primary completion later than 30 of the 30 other live ones, and was the 104th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →25 of the 111 studies in Spinal Cord Injuries with a site in Switzerland are open now. Recruiting first, the newest first:
NovaGo Therapeutics AG · Sites in Switzerland, Germany
Ages 18–75
Swiss Paraplegic Research, Nottwil · Sites in Switzerland
Ages 18–70
Swiss Paraplegic Research, Nottwil · Sites in Switzerland
Ages 18+
Swiss Paraplegic Research, Nottwil · Sites in Switzerland
Ages 18–75
Swiss Paraplegic Research, Nottwil · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 1 · Phase 4 2
First in 2004; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 21 across the 72 interventional studies, 50 across the 39 observational. Of the 72 that completed or were terminated, 4 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 111 have an industry lead sponsor. The 10 most frequent:
Ecole Polytechnique Fédérale de Lausanne is the lead sponsor of 21 studies on the registry; 11 are open to participants now.
Ecole Polytechnique Fédérale de Lausanne has 8 studies filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
10 of the studies in Spinal Cord Injuries with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01571531University of ZurichEuropean Multicentre Study of Human Spinal Cord Injury | 2026-12 |
| NCT03053791University of ZurichDeep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait | 2026-12 |
| NCT07739134ETH ZurichMultimodal Tracking of Therapy Activity and Effort During Rehabilitation | 2026-12-30 |
| NCT06845904Ecole Polytechnique Fédérale de LausanneStudy on Preliminary Safety and Efficacy of Epidural Electrical Stimulation to Manage Lower Urinary Tract Dysfunction After Spinal Cord Injury | 2027-02 |
| NCT06817577NovaGo Therapeutics AGNG004 in Spinal Cord Injury Patients | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 111 studies in Spinal Cord Injuries with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The EIGER study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support and promote recovery of ambulatory functions, such as walking, in people with subacute and chronic spinal cord injury.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants having sustained the injury less than 6 weeks prior to baseline (subacute). Participants will be provided with the ARC-IM Therapy.
Device: ARC-IM Therapy
Participants having sustained the injury more than 1 year prior to enrollment (chronic). Participants will be provided with the ARC-IM Therapy.
Device: ARC-IM Therapy
All participants will be treated with ARC-IM Therapy. The ARC-IM Lumbar System is intended to deliver electrical impulses to the lumbosacral region of the spinal cord to support ambulatory functions in people with SCI.
Occurrence of Serious Adverse Events and Adverse Events that are deemed related or possibly related to the study procedure or to ARC-IM Therapy, from implantation up to the end of the study.
Assess the preliminary safety of ARC-IM Therapy in participants with subacute and chronic SCI.
Time frame: Continuously throughout the study (up to 6 years)
American Spinal Injury Association (ASIA) International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI)
The ASIA ISNCSCI is a clinical examination used to assess the motor and sensory impairment and severity of a spinal cord injury.
Time frame: At Eligibility, and at 6 weeks, 16 weeks, 42 weeks post-surgery
10-Meter Walk Test (10MWT)
The 10MWT assesses walking speed in meters per second over a short duration. It measures the time taken by the subjects to walk 10 meters. The test will be performed twice, at self-selected and at maximum velocity. Participants can use their habitual assistive device. The test will be conducted both with and without stimulation.
Time frame: At Baseline, and at 6 weeks, 16 weeks, ad 42 weeks post-surgery
6-Minute Walk Test (6MWT)
The 6MWT assesses endurance by measuring the distance in meters a participant walks in 6 minutes. Participants can use their habitual assistive device and can take as many standing breaks as they need, but the timer will not be paused. This test will be conducted both with and without stimulation.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
Timed Up and Go (TUG)
The TUG evaluates functional mobility. Participants begin seated, then stand up, walk 3 meters, turn around, walk back, and sit down. The time taken to complete the sequence is recorded. Assistive devices may be used if necessary. The test will be conducted both with and without stimulation.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
Walking Index for Spinal Cord Injury version II (WISCI II)
The WISCI II assesses the extent and nature of assistance a person with SCI requires to walk, using an ordinal scale of 20 levels, ranging from the most severe impairment (level 0) to the least severe impairment (level 20). The level is determined based on the use of assistive devices, braces, and the physical assistance of one or more persons. The test will be conducted both with and without stimulation.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
Spinal Cord Injury Functional Ambulation Inventory (SCI-FAI)
The SCI-FAI assesses functional walking ability. It is an observational gait assessment that includes 3 key domains of walking function, where 0 is the minimum and worst outcome: gait parameters (maximum score of 20 points), assistive device (each limb scored individually - maximum score of 14 points), and temporal distance (maximum score of 5 points). The test will be conducted both with and without stimulation.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
Gait Analysis
Multifactorial gait analysis that relies on high-precision recordings of whole-body kinematics and kinetics of each gait cycle will be performed. The test will be conducted both with and without stimulation.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
Goal Attainment Scale (GAS)
The GAS is used to evaluate the participant's progress toward one or more personalized goal(s), which are individually defined by the participant. Each goal is scored on a standardized scale ranging from -2 (outcome is much less than expected) to +2 (outcome is much more than expected), allowing to assess to which extent the goal is met. The form will be completed for both with and without stimulation condition.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
Berg Balance Scale (BBS)
The BBS assesses static and dynamic balance through 14 tasks, such as standing, reaching, and turning. Each item is scored on a 5-point scale (0-4) with higher scores meaning better ability to perform the assessed activity. Item scores are then summed, with a maximum score of 56. The use of assistive devices is not allowed. The test will be conducted both with and without stimulation.
Time frame: At Baseline, and at 6 weeks, 16 weeks, 42 weeks post-surgery
ARC-IM stimulation usage log
Independent use of the ARC-IM Lumbar System by study participants will be evaluated through analysis of the ARC-IM stimulation usage log.
Time frame: At 6 weeks, 16 weeks, 42 weeks post-surgery, and at the end of the study
Integration of ARC-IM Therapy within the standard-of-care
Integration of ARC-IM Therapy within the standard-of-care for subacute SCI will be evaluated by quantifying its use within standard clinical mobility rehabilitation procedures. This will be achieved by extracting and comparing data of the Stimulation Usage Log and Participant's Calendar Log.
Time frame: At 6 weeks, 16 weeks, and 42 weeks post-surgery
EES Evoked Muscle Response
Effect of ARC-IM Therapy on the modulation of the spinal cord will be evaluated through electrophysiological assessments that will quantify the muscle responses to EES and adaptation of these responses over time.
Time frame: Every 2 days during the mapping phase, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
Function In Sitting Test for Spinal Cord Injury (FIST-SCI)
Effect of ARC-IM Therapy on trunk stability will be evaluated using the FIST-SCI. The FIST-SCI assesses sitting balance. It evaluates sensory, motor, proactive, reactive, and steady state balance factors based on 14 items, each scored on an ordinal scale from 0 to 4, where 0 means complete assistance is needed to perform the task successfully, and 4 means can complete the task independently and successfully. The test will be conducted both with and without stimulation.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks after surgery
Modified Ashworth Scale (MAS)
Effect of ARC-IM Therapy on muscle tone will be evaluated using the MAS. The MAS assesses spasticity in a participant's upper and lower limb, by rating the resistance of a muscle to passive movement at a single joint on a 6-point nominal scale, where 0 means no increase in tone, and 5 means affected parts are rigid in flexion or extension. The clinical examination will be performed both with and without stimulation on different days at similar times. Antispastic medication and time points of test/medication intake will be documented.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
Spinal Cord Assessment Tool for Spastic Reflexes (SCATS)
Effect of ARC-IM Therapy on muscle tone will be evaluated using the SCATS. The SCATS assesses 3 types of spastic motor behaviors in SCI patients - clonus, flexor spasms, and extensor spasms. The clinical examination will be performed both with and without stimulation. Antispastic medication and start time of the test will be documented for inter-test reliability.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
Spinal Cord Injury - Quality of Life Short form (SCI-QoL SF)
Effect of ARC-IM Therapy on quality of life will be evaluated with the SCI-QoL SF. The SCI-QoL SF is a PROM for individuals with SCI. It is divided into 4 domains (emotional health, physical-medical health, social participation, physical functioning) with a selection of 22 subdomains. Each subdomain has several items. The participant rates each item with a number between 1 and 5 according to the extent to which the statement it contains applies to them. Each subdomain is scored separately. The higher the score, the higher the participant's perceived quality of life.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L)
Effect of ARC-IM Therapy on quality of life for chronic SCI participants will be evaluated with the EQ-5D-5L questionnaire. The EQ-5D-5L is a PROM that describes the patient's health state for five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Time frame: At Baseline, at 6 weeks, 16 weeks, and 42 weeks post-surgery, and yearly until the end of study
Patient Global Impression of Change (PGI-C)
Effect of ARC-IM Therapy on the subjective change of overall status will be evaluated with the PGI-C. The PGI-C is a single-item questionnaire to measure the change of clinical status, injury severity, or injury improvement, and evaluate the response of a condition to the given therapy. It is a 7-point scale where the participant rates his/her improvement or deterioration on a scale from "1 = very much improved" to "7 = very much worse".
Time frame: At 6 weeks, 16 weeks, and 42 weeks post-surgery
Spinal Cord Independence Measure (SCIM) III
Effect of ARC-IM Therapy on functional independence in daily living will be evaluated with the SCIM III score. The SCIM III is a disability score that addresses functional ability in daily living in people with SCI. Three specific areas are assessed: self-care (0-20 points), respiration and sphincter management (0-40 points), and mobility (0-40 points). The form will be filled out as per stimulation use of the participant in his/her daily life activities for with or without stimulation condition. Total score ranges between 0 and 100 points, with higher scores reflecting greater independence.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
System Usability Scale (SUS)
The SUS is a standardized post-usability test questionnaire comprised of 10 Likert-scale questions used to evaluate the usability of the investigational system. To collect the SUS score, participants rate how strongly they agree or disagree with statements on a 1 (strongly disagree) to 5 (strongly agree) scale.
Time frame: At 6 weeks, 16 weeks, and 42 weeks post-surgery
EMSCI Pain Assessment Form (EPAF)
Effect of ARC-IM Therapy on pain will be evaluated with the EPAF. The EPAF is used for classification of existing pain problems in people with SCI. The clinical assessment form consists of 12 items and follows the international guidelines and recommendations for the clinical documentation and assessment of pain in SCI. One overall form will be completed summarizing with and without stimulation condition.
Time frame: At Baseline, and at 6 weeks, 16 weeks, and 42 weeks post-surgery
Dual-Energy X-Ray Absorptiometry (DEXA)
Effect of ARC-IM Therapy on bone mineral density will be evaluated using DEXA. Participants will lie in a supine position during the scan, following standardized protocols.
Time frame: At Baseline and at 42 weeks post-surgery
Quantitative Computed Tomography (QCT)-Scan
Effect of ARC-IM Therapy on muscle mass will be evaluated using QCT-Scan. The QCT-Scan is used to assess muscle mass by providing high-resolution cross-sectional images of the thigh and the trunk. It allows for precise measurement of muscle volume and composition. Participants will undergo the scan in a supine position, and standardized protocols will be used to ensure consistency across time points.
Time frame: At Eligibility and at 42 weeks post-surgery
Additional User Feedback
The Additional User Feedback is a form designed to collect qualitative feedback from participants regarding their interaction with the ARCIM Lumbar System. It includes rating items to evaluate satisfaction (from "not satisfied at all" to "very satisfied") and open-ended questions addressing ease of use, satisfaction with system components such as battery life, charging time, connection stability, and overall comfort during use.
Time frame: At 6 weeks, 16 weeks, and 42 weeks post-surgery
Start is estimated for Apr 2026; primary completion for Apr 2032, 72 months later.
Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 72 months is above that.
Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ecole Polytechnique Fédérale de Lausanne